Safe­ty qualms in MyoKar­dia mid-stage study cause in­vestors to pause

Ahead of the piv­otal da­ta read­out of MyoKar­dia’s lead drug, mava­camten, in pa­tients with ob­struc­tive hy­per­trophic car­diomy­opa­thy (HCM), in­vestors took is­sue with the drug’s safe­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER